Rivaroxaban CAS 366789-02-8 Pite> 99.5% (HPLC) Faktori API High Quality
Manifakti Pwovizyon pou Rivaroxaban Entèmedyè ki gen rapò:
(S)-(+)-Glycidyl Phtalimide CAS 161596-47-0
4-(4-Aminophenyl)morpholin-3-one CAS 438056-69-0
Rivaroxaban Entèmedyè CAS 446292-07-5
5-Chlorothiophene-2-Carboxylic Asid CAS 24065-33-6
5-Chlorothiophene-2-Carbonyl Chloride CAS 42518-98-9
Rivaroxaban API CAS 366789-02-8
Non Chimik | Rivaroxaban |
Sinonim | (S)-Rivaroxaban;(S)-5-Chloro-N-((2-oxo-3-(4-(3-oxomorpholino)phenyl)-oxazolidin-5-yl)methyl)thiophene-2-carbox;BAY 59-7939 |
Nimewo CAS | 366789-02-8 |
Estati Stock | Nan Stock, Pwodiksyon Echèl Jiska Tòn |
Fòmil molekilè | C19H18ClN3O5S |
Pwa molekilè | 435,88 |
Mak | Ruifu Chimik |
Atik | Espesifikasyon |
Aparans | Poud blan oswa prèske blan |
Idantifikasyon A | Absòpsyon enfrawouj Rivaroxaban koresponn ak estanda referans yo |
Idantifikasyon B | Tan an retansyon nan pik prensipal la nan solisyon echantiyon an koresponn ak sa yo ki nan solisyon an konvnab sistèm, jan yo jwenn nan pite a enantiomeric. |
Enantiomeric Pite | RVX RC01: ≤0.15% |
Imidite (KF) | ≤0.50% |
Sulfated Ash | ≤0.10% |
Metal lou | ≤20ppm |
Asid Acetic | ≤5000ppm |
Sibstans ki gen rapò (HPLC) | |
RVX RC02 | ≤0.15% |
RVX RC03 | ≤0.15% |
RVX RC04 | ≤0.15% |
RVX RC05 | ≤0.15% |
RVX RC06 | ≤0.15% |
RVX RC07 | ≤0.15% |
RVX RC08 | ≤0.15% |
Nenpòt lòt enpurte endividyèl | ≤0.10% |
Enpurte total | <0.50% |
Solvants rezidyèl (GC) | |
Etanòl | ≤5000ppm |
Toluèn | ≤890ppm |
Triethylamine | ≤320ppm |
Pite / Metòd analiz | > 99.5% (HPLC) (sou baz anidrid) |
Tès Creole | Enterprise Standard |
Itilizasyon | API;Dwòg antitronbotik;FXa Inibitè |
Pake: Boutèy, sache papye aliminyòm, 25kg / tanbou katon, oswa selon kondisyon kliyan an.
Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè ak imidite.
![1](https://a395.goodao.net/uploads/15.jpg)
![](https://a395.goodao.net/uploads/23.jpg)
Rivaroxaban(CAS:366789-02-8) (Xarelto, Bayer) se yon anticoagulant oral.Li se yon faktè dirèk aktif oral Xa inibitè.Rivaroxaban endike pou 'tretman tronboz venn gwo twou san fon ak anbolis poumon, ak prevansyon tronboz venn fon frekan ak anbolis poumon nan granmoun'.Pou premye tretman anbolis pulmonè egi, dòz la rekòmande nan rivaroxaban se 15 mg de fwa pa jou pou premye 21 jou yo ki te swiv pa 20 mg yon fwa chak jou pou kontinye tretman ak prevansyon nan tronboanbolis venn frekan.Fibrilasyon atrial ki pa Valvular (NVAF) pou anpeche konjesyon serebral ak anbolis sistemik.Tretman egi VTE ak prevansyon VTE renouvlab [pou tronboz venn gwo twou san fon (DVT) ak anbolis poumon (PE)].Prevansyon nan evènman tronboembolic venn (VTE) nan operasyon ochwa total ranplasman anch oswa jenou (THR, TKR).
-
Rivaroxaban CAS 366789-02-8 Pite > 99.5% (HPLC...
-
(S)-(+)-Glycidyl Phtalimide CAS 161596-47-0 Pu...
-
4-(4-Aminophenyl)morpholin-3-One CAS 438056-69-...
-
Rivaroxaban Entèmedyè CAS 446292-07-5 Pite...
-
5-Chlorothiophene-2-Carboxylic Asid CAS 24065-3...
-
5-Chlorothiophene-2-Carbonyl Chloride CAS 42518...
-
4,5-Dichlorothiophene-2-Carboxylic Asid CAS 311...